stockrow
Saturday 7 November 2026
Export LYEL’s income statement to Excel — free account
Lyell Immunopharma, Inc.
LYEL Healthcare Biotechnology
Lyell Immunopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36,000.00, down 41.0% from fiscal 2024.
- Revenue
- −80.0%
- EPS
- +12.7%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
14.82
0.18
−1.20%
Follow LYEL
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
14,614.52 | 14,155.89 | 12,157.93 | 15,948.56 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(16.31) | (11.40) | (9.68) | (6.92) | |
P/B ratio |
2.12 | 1.60 | 1.40 | 1.24 | |
Price to Tangible BV |
2.12 | 1.60 | 1.40 | 1.24 | |
EV/Sales |
7,747.29 | 5,961.60 | 4,598.60 | 4,141.50 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.86) | (1.38) | (0.93) | (0.45) | |
EV/FCF |
(1.45) | (1.05) | (0.71) | (0.34) | |
Quick Ratio |
5.00 | 6.88 | 5.12 | 3.83 | |
Current Ratio |
5.28 | 7.23 | 5.36 | 4.02 | |
Net Debt/EBITDA |
1.96 | 5.93 | 4.44 | 3.77 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.23 | 1.59 | 0.76 | 0.76 | |
Capex/Depreciation |
(31.02) | (0.06) | (0.18) | 0.00 | |
Research and Development Expense of Revenue |
869,983.33% | 1,830,200.00% | 988,100.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
176,933.33% | 477,750.00% | 239,400.00% | 309,900.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
426,150.00% | 214,750.00% | 113,300.00% | 150,466.67% | |
Graham Net Nets |
0.32 | 0.43 | 0.41 | 0.44 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(52.96%) | (68.79%) | (91.32%) | (128.29%) | |
Free Cash Flow Yield |
(36.44%) | (39.95%) | (53.27%) | (75.60%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.89) | (1.76) | (1.45) | (1.41) | |
Capex per Share |
(2.43) | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(4.31) | (1.76) | (1.46) | (1.41) | |
Cash per Share |
14.46 | 11.61 | 8.74 | 7.25 | |
Shareholders Equity per Share |
14.52 | 12.51 | 10.01 | 7.89 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.52 | 12.51 | 10.01 | 7.89 | |
Free Cash Flow |
(73.73) | (38.60) | (34.17) | (34.57) | |
Working Capital |
211.53 | 230.36 | 173.67 | 139.94 | |
Capital Expenditures |
(41.47) | (0.09) | (0.25) | — | |
Net Current Asset Value |
169.09 | 190.34 | 136.20 | 105.08 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
6,912.50 | 44.50 | 62.75 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
4.13 | 4.60 | 3.63 | 3.30 | |
Average Assets |
415.46 | 390.21 | 348.30 | 340.91 | |
Average Common Equity |
315.51 | 305.09 | 266.37 | 260.92 |
Columns are period end dates · fundamentals updated 4 Nov 2026